Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets

We conducted an open-label, dose titration study to assess the efficacy and tolerability of controlled-release oxycodone in the therapy of cancer pain management, starting with a newly developed 5 mg tablet every 12 h. Twenty-two Japanese cancer patients with pain who had not been taking opioid anal...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Japanese journal of clinical oncology 2004-10, Vol.34 (10), p.608-614
Hauptverfasser: Koizumi, Wasaburo, Toma, Hiroshi, Watanabe, Ken-ichi, Katayama, Kanji, Kawahara, Masaaki, Matsui, Kaoru, Takiuchi, Hiroya, Yoshino, Kunitoshi, Araki, Nobuhito, Kodama, Ken, Kimura, Hideyuki, Kono, Ichiro, Hasegawa, Hiroyasu, Hatanaka, Kaoru, Hiraga, Kazuaki, Takeda, Fumikazu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 614
container_issue 10
container_start_page 608
container_title Japanese journal of clinical oncology
container_volume 34
creator Koizumi, Wasaburo
Toma, Hiroshi
Watanabe, Ken-ichi
Katayama, Kanji
Kawahara, Masaaki
Matsui, Kaoru
Takiuchi, Hiroya
Yoshino, Kunitoshi
Araki, Nobuhito
Kodama, Ken
Kimura, Hideyuki
Kono, Ichiro
Hasegawa, Hiroyasu
Hatanaka, Kaoru
Hiraga, Kazuaki
Takeda, Fumikazu
description We conducted an open-label, dose titration study to assess the efficacy and tolerability of controlled-release oxycodone in the therapy of cancer pain management, starting with a newly developed 5 mg tablet every 12 h. Twenty-two Japanese cancer patients with pain who had not been taking opioid analgesics over the previous 2 weeks were enrolled. The length of time and the dose needed to attain stable and adequate pain control were evaluated in addition to the assessment of analgesic efficacy and safety during the study period. Eighteen patients in the efficacy population (18 out of 20, 90%) attained stable, adequate pain control. Two-thirds of the patients attained stable, adequate pain control without any dose titration. The mean length of time was 1.2 days. In these patients, the pain was significantly reduced in intensity, even at 1 h after the initial dose intake. Fifteen patients (68%) reported at least one side effect, but only one patient had to withdraw from the study because of a side effect. The results suggest that controlled-release oxycodone tablets offered stable and adequate pain control within a short period of time in most Japanese cancer patients who have not been taking opioid analgesics, and could be effectively titrated against pain from a starting dose of 5 mg every 12 h. This indicates that a lower strength controlled-release oxycodone formulation may make it possible to start and titrate the dose more appropriately and carefully in patients who are sensitive to opioid analgesics.
doi_str_mv 10.1093/jjco/hyh104
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67178994</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67178994</sourcerecordid><originalsourceid>FETCH-LOGICAL-c254t-f07cf65ab0b3c5d2f0db3fe2fe6af1d0fc67198c4bad98d94e593e2fdb0301bc3</originalsourceid><addsrcrecordid>eNpdkU1v1DAQQC1ERZfCiTuyOPRSQu04TuIjqsqHVKkXOEcTe7zrlWMH20ubP8NvJdUuQnCaw7x5GukR8oazD5wpcb3f63i9W3acNc_IhjetrERb8-dkw0TbV3XP-Tl5mfOeMSb7pntBzrmUijdSbcivW2udBr1QCIaW6DHB6LwrC42WaggaE53BBTpBgC1OGAp9cGVHdQwlRe_RVAk9QkYaHxcdTQxIC4weS6brXZxddKYK4H7iP8IZiltt-T3NBVJxYXsUSzpt_whekTMLPuPr07wg3z_dfrv5Ut3df_568_Gu0rVsSmVZp20rYWSj0NLUlplRWKwttmC5YVa3HVe9bkYwqjeqQanEujYjE4yPWlyQy6N3TvHHAXMZJpc1eg8B4yEP63nXK9Ws4Lv_wH08pLD-NtS841yqrl2hqyOkU8w5oR3m5CZIy8DZ8NRseGo2HJut9NuT8jBOaP6yp0jiNw2cmAo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217115976</pqid></control><display><type>article</type><title>Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Freely Accessible Japanese Titles</source><creator>Koizumi, Wasaburo ; Toma, Hiroshi ; Watanabe, Ken-ichi ; Katayama, Kanji ; Kawahara, Masaaki ; Matsui, Kaoru ; Takiuchi, Hiroya ; Yoshino, Kunitoshi ; Araki, Nobuhito ; Kodama, Ken ; Kimura, Hideyuki ; Kono, Ichiro ; Hasegawa, Hiroyasu ; Hatanaka, Kaoru ; Hiraga, Kazuaki ; Takeda, Fumikazu</creator><creatorcontrib>Koizumi, Wasaburo ; Toma, Hiroshi ; Watanabe, Ken-ichi ; Katayama, Kanji ; Kawahara, Masaaki ; Matsui, Kaoru ; Takiuchi, Hiroya ; Yoshino, Kunitoshi ; Araki, Nobuhito ; Kodama, Ken ; Kimura, Hideyuki ; Kono, Ichiro ; Hasegawa, Hiroyasu ; Hatanaka, Kaoru ; Hiraga, Kazuaki ; Takeda, Fumikazu</creatorcontrib><description>We conducted an open-label, dose titration study to assess the efficacy and tolerability of controlled-release oxycodone in the therapy of cancer pain management, starting with a newly developed 5 mg tablet every 12 h. Twenty-two Japanese cancer patients with pain who had not been taking opioid analgesics over the previous 2 weeks were enrolled. The length of time and the dose needed to attain stable and adequate pain control were evaluated in addition to the assessment of analgesic efficacy and safety during the study period. Eighteen patients in the efficacy population (18 out of 20, 90%) attained stable, adequate pain control. Two-thirds of the patients attained stable, adequate pain control without any dose titration. The mean length of time was 1.2 days. In these patients, the pain was significantly reduced in intensity, even at 1 h after the initial dose intake. Fifteen patients (68%) reported at least one side effect, but only one patient had to withdraw from the study because of a side effect. The results suggest that controlled-release oxycodone tablets offered stable and adequate pain control within a short period of time in most Japanese cancer patients who have not been taking opioid analgesics, and could be effectively titrated against pain from a starting dose of 5 mg every 12 h. This indicates that a lower strength controlled-release oxycodone formulation may make it possible to start and titrate the dose more appropriately and carefully in patients who are sensitive to opioid analgesics.</description><identifier>ISSN: 0368-2811</identifier><identifier>ISSN: 1465-3621</identifier><identifier>EISSN: 1465-3621</identifier><identifier>DOI: 10.1093/jjco/hyh104</identifier><identifier>PMID: 15591459</identifier><language>eng</language><publisher>England: Oxford Publishing Limited (England)</publisher><subject>Aged ; Aged, 80 and over ; Analgesics, Opioid - administration &amp; dosage ; Delayed-Action Preparations ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Lung Neoplasms - physiopathology ; Male ; Middle Aged ; Neoplasms - physiopathology ; Oxycodone - administration &amp; dosage ; Pain Measurement - methods ; Pain, Intractable - drug therapy ; Patient Acceptance of Health Care ; Stomach Neoplasms - physiopathology ; Tablets ; Titrimetry</subject><ispartof>Japanese journal of clinical oncology, 2004-10, Vol.34 (10), p.608-614</ispartof><rights>Copyright Oxford University Press(England) Oct 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c254t-f07cf65ab0b3c5d2f0db3fe2fe6af1d0fc67198c4bad98d94e593e2fdb0301bc3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15591459$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koizumi, Wasaburo</creatorcontrib><creatorcontrib>Toma, Hiroshi</creatorcontrib><creatorcontrib>Watanabe, Ken-ichi</creatorcontrib><creatorcontrib>Katayama, Kanji</creatorcontrib><creatorcontrib>Kawahara, Masaaki</creatorcontrib><creatorcontrib>Matsui, Kaoru</creatorcontrib><creatorcontrib>Takiuchi, Hiroya</creatorcontrib><creatorcontrib>Yoshino, Kunitoshi</creatorcontrib><creatorcontrib>Araki, Nobuhito</creatorcontrib><creatorcontrib>Kodama, Ken</creatorcontrib><creatorcontrib>Kimura, Hideyuki</creatorcontrib><creatorcontrib>Kono, Ichiro</creatorcontrib><creatorcontrib>Hasegawa, Hiroyasu</creatorcontrib><creatorcontrib>Hatanaka, Kaoru</creatorcontrib><creatorcontrib>Hiraga, Kazuaki</creatorcontrib><creatorcontrib>Takeda, Fumikazu</creatorcontrib><title>Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets</title><title>Japanese journal of clinical oncology</title><addtitle>Jpn J Clin Oncol</addtitle><description>We conducted an open-label, dose titration study to assess the efficacy and tolerability of controlled-release oxycodone in the therapy of cancer pain management, starting with a newly developed 5 mg tablet every 12 h. Twenty-two Japanese cancer patients with pain who had not been taking opioid analgesics over the previous 2 weeks were enrolled. The length of time and the dose needed to attain stable and adequate pain control were evaluated in addition to the assessment of analgesic efficacy and safety during the study period. Eighteen patients in the efficacy population (18 out of 20, 90%) attained stable, adequate pain control. Two-thirds of the patients attained stable, adequate pain control without any dose titration. The mean length of time was 1.2 days. In these patients, the pain was significantly reduced in intensity, even at 1 h after the initial dose intake. Fifteen patients (68%) reported at least one side effect, but only one patient had to withdraw from the study because of a side effect. The results suggest that controlled-release oxycodone tablets offered stable and adequate pain control within a short period of time in most Japanese cancer patients who have not been taking opioid analgesics, and could be effectively titrated against pain from a starting dose of 5 mg every 12 h. This indicates that a lower strength controlled-release oxycodone formulation may make it possible to start and titrate the dose more appropriately and carefully in patients who are sensitive to opioid analgesics.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analgesics, Opioid - administration &amp; dosage</subject><subject>Delayed-Action Preparations</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - physiopathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasms - physiopathology</subject><subject>Oxycodone - administration &amp; dosage</subject><subject>Pain Measurement - methods</subject><subject>Pain, Intractable - drug therapy</subject><subject>Patient Acceptance of Health Care</subject><subject>Stomach Neoplasms - physiopathology</subject><subject>Tablets</subject><subject>Titrimetry</subject><issn>0368-2811</issn><issn>1465-3621</issn><issn>1465-3621</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1v1DAQQC1ERZfCiTuyOPRSQu04TuIjqsqHVKkXOEcTe7zrlWMH20ubP8NvJdUuQnCaw7x5GukR8oazD5wpcb3f63i9W3acNc_IhjetrERb8-dkw0TbV3XP-Tl5mfOeMSb7pntBzrmUijdSbcivW2udBr1QCIaW6DHB6LwrC42WaggaE53BBTpBgC1OGAp9cGVHdQwlRe_RVAk9QkYaHxcdTQxIC4weS6brXZxddKYK4H7iP8IZiltt-T3NBVJxYXsUSzpt_whekTMLPuPr07wg3z_dfrv5Ut3df_568_Gu0rVsSmVZp20rYWSj0NLUlplRWKwttmC5YVa3HVe9bkYwqjeqQanEujYjE4yPWlyQy6N3TvHHAXMZJpc1eg8B4yEP63nXK9Ws4Lv_wH08pLD-NtS841yqrl2hqyOkU8w5oR3m5CZIy8DZ8NRseGo2HJut9NuT8jBOaP6yp0jiNw2cmAo</recordid><startdate>200410</startdate><enddate>200410</enddate><creator>Koizumi, Wasaburo</creator><creator>Toma, Hiroshi</creator><creator>Watanabe, Ken-ichi</creator><creator>Katayama, Kanji</creator><creator>Kawahara, Masaaki</creator><creator>Matsui, Kaoru</creator><creator>Takiuchi, Hiroya</creator><creator>Yoshino, Kunitoshi</creator><creator>Araki, Nobuhito</creator><creator>Kodama, Ken</creator><creator>Kimura, Hideyuki</creator><creator>Kono, Ichiro</creator><creator>Hasegawa, Hiroyasu</creator><creator>Hatanaka, Kaoru</creator><creator>Hiraga, Kazuaki</creator><creator>Takeda, Fumikazu</creator><general>Oxford Publishing Limited (England)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>200410</creationdate><title>Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets</title><author>Koizumi, Wasaburo ; Toma, Hiroshi ; Watanabe, Ken-ichi ; Katayama, Kanji ; Kawahara, Masaaki ; Matsui, Kaoru ; Takiuchi, Hiroya ; Yoshino, Kunitoshi ; Araki, Nobuhito ; Kodama, Ken ; Kimura, Hideyuki ; Kono, Ichiro ; Hasegawa, Hiroyasu ; Hatanaka, Kaoru ; Hiraga, Kazuaki ; Takeda, Fumikazu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c254t-f07cf65ab0b3c5d2f0db3fe2fe6af1d0fc67198c4bad98d94e593e2fdb0301bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analgesics, Opioid - administration &amp; dosage</topic><topic>Delayed-Action Preparations</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - physiopathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasms - physiopathology</topic><topic>Oxycodone - administration &amp; dosage</topic><topic>Pain Measurement - methods</topic><topic>Pain, Intractable - drug therapy</topic><topic>Patient Acceptance of Health Care</topic><topic>Stomach Neoplasms - physiopathology</topic><topic>Tablets</topic><topic>Titrimetry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koizumi, Wasaburo</creatorcontrib><creatorcontrib>Toma, Hiroshi</creatorcontrib><creatorcontrib>Watanabe, Ken-ichi</creatorcontrib><creatorcontrib>Katayama, Kanji</creatorcontrib><creatorcontrib>Kawahara, Masaaki</creatorcontrib><creatorcontrib>Matsui, Kaoru</creatorcontrib><creatorcontrib>Takiuchi, Hiroya</creatorcontrib><creatorcontrib>Yoshino, Kunitoshi</creatorcontrib><creatorcontrib>Araki, Nobuhito</creatorcontrib><creatorcontrib>Kodama, Ken</creatorcontrib><creatorcontrib>Kimura, Hideyuki</creatorcontrib><creatorcontrib>Kono, Ichiro</creatorcontrib><creatorcontrib>Hasegawa, Hiroyasu</creatorcontrib><creatorcontrib>Hatanaka, Kaoru</creatorcontrib><creatorcontrib>Hiraga, Kazuaki</creatorcontrib><creatorcontrib>Takeda, Fumikazu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koizumi, Wasaburo</au><au>Toma, Hiroshi</au><au>Watanabe, Ken-ichi</au><au>Katayama, Kanji</au><au>Kawahara, Masaaki</au><au>Matsui, Kaoru</au><au>Takiuchi, Hiroya</au><au>Yoshino, Kunitoshi</au><au>Araki, Nobuhito</au><au>Kodama, Ken</au><au>Kimura, Hideyuki</au><au>Kono, Ichiro</au><au>Hasegawa, Hiroyasu</au><au>Hatanaka, Kaoru</au><au>Hiraga, Kazuaki</au><au>Takeda, Fumikazu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets</atitle><jtitle>Japanese journal of clinical oncology</jtitle><addtitle>Jpn J Clin Oncol</addtitle><date>2004-10</date><risdate>2004</risdate><volume>34</volume><issue>10</issue><spage>608</spage><epage>614</epage><pages>608-614</pages><issn>0368-2811</issn><issn>1465-3621</issn><eissn>1465-3621</eissn><abstract>We conducted an open-label, dose titration study to assess the efficacy and tolerability of controlled-release oxycodone in the therapy of cancer pain management, starting with a newly developed 5 mg tablet every 12 h. Twenty-two Japanese cancer patients with pain who had not been taking opioid analgesics over the previous 2 weeks were enrolled. The length of time and the dose needed to attain stable and adequate pain control were evaluated in addition to the assessment of analgesic efficacy and safety during the study period. Eighteen patients in the efficacy population (18 out of 20, 90%) attained stable, adequate pain control. Two-thirds of the patients attained stable, adequate pain control without any dose titration. The mean length of time was 1.2 days. In these patients, the pain was significantly reduced in intensity, even at 1 h after the initial dose intake. Fifteen patients (68%) reported at least one side effect, but only one patient had to withdraw from the study because of a side effect. The results suggest that controlled-release oxycodone tablets offered stable and adequate pain control within a short period of time in most Japanese cancer patients who have not been taking opioid analgesics, and could be effectively titrated against pain from a starting dose of 5 mg every 12 h. This indicates that a lower strength controlled-release oxycodone formulation may make it possible to start and titrate the dose more appropriately and carefully in patients who are sensitive to opioid analgesics.</abstract><cop>England</cop><pub>Oxford Publishing Limited (England)</pub><pmid>15591459</pmid><doi>10.1093/jjco/hyh104</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0368-2811
ispartof Japanese journal of clinical oncology, 2004-10, Vol.34 (10), p.608-614
issn 0368-2811
1465-3621
1465-3621
language eng
recordid cdi_proquest_miscellaneous_67178994
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Freely Accessible Japanese Titles
subjects Aged
Aged, 80 and over
Analgesics, Opioid - administration & dosage
Delayed-Action Preparations
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Lung Neoplasms - physiopathology
Male
Middle Aged
Neoplasms - physiopathology
Oxycodone - administration & dosage
Pain Measurement - methods
Pain, Intractable - drug therapy
Patient Acceptance of Health Care
Stomach Neoplasms - physiopathology
Tablets
Titrimetry
title Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T02%3A57%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20tolerability%20of%20cancer%20pain%20management%20with%20controlled-release%20oxycodone%20tablets%20in%20opioid-naive%20cancer%20pain%20patients,%20starting%20with%205%20mg%20tablets&rft.jtitle=Japanese%20journal%20of%20clinical%20oncology&rft.au=Koizumi,%20Wasaburo&rft.date=2004-10&rft.volume=34&rft.issue=10&rft.spage=608&rft.epage=614&rft.pages=608-614&rft.issn=0368-2811&rft.eissn=1465-3621&rft_id=info:doi/10.1093/jjco/hyh104&rft_dat=%3Cproquest_cross%3E67178994%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217115976&rft_id=info:pmid/15591459&rfr_iscdi=true